期刊文献+

HIV的病原学研究进展 被引量:2

Advance on HIV Biology and Pathogensis
下载PDF
导出
摘要 人类免疫缺陷病毒(Human Immunodeficiency Virus,简称HIV)是导致艾滋病的病原体。研究HIV的病原学是认识HIV的致病机理、寻找有效的抗病毒治疗的靶位、设计HIV疫苗和诊断方法并最终控制艾滋病的基础。自从1983年HIV被分离出以来,HIV的病原学研究取得了长足进展:阐明了HIV的形态、结构以及病毒各个组成部分的功能;了解了HIV的复制和生命周期,并对病毒复制的调控有了基本的认识;对HIV在体内的动态和变异规律有了深入的了解;在上述认识的基础上,对HIV的致病机理以及病毒与宿主细胞的相互作用进行了深入的研究并取得了良好的进展。但是,艾滋病的抗病毒治疗和特异性免疫预防还远没有解决。开展深入的艾滋病病原学和致病机理研究,进一步揭示病毒复制、调控和致病的分子机制,阐明病毒与宿主细胞的相互作用,是发展新型抗药物、设计有效的HIV疫苗的前提和保证。本文概括了HIV病原学研究领域的主要进展,并提出了今后研究的展望。 Human Immunodeficiency Virus (HIV) is the pathogen of AIDS. Research on HIV etiology is the basis of understanding HIV pathogenesis, searching for the targets of antiretroviral therapy, designing of effective HIV vaccine and diagnostic methods. Since HIV was isolated in 1983, the biology study has made great progress. The shape, structure and function of each ingredient of the viral particle have been clarified. The replication and life cycle of the virus have been understood, the control and regulation of virus replication have been revealed. The dynamic and variation of the virus have been comprehended. On the basis of the these knowledge, the pathogenesis of HIV and the interaction between HIV and host cell have been bright to light. However, HIV antiretroviral therapy and specific immune prevention are still great problems, the advanced research on HIV biology and pathogenesis is urgently needed for revealing molecular mechanism of HIV replication, regulation and pathogenesis, clarifying the interaction between HIV and host cell and development of new antiretroviral agents and vaccine.
作者 李敬云
出处 《科技导报》 CAS CSCD 2005年第7期9-16,共8页 Science & Technology Review
关键词 病原学 人类免疫缺陷病毒 艾滋病 致病机理 etiology, Human Immunodeficiency Virus, AIDS, pathogenesis
  • 相关文献

参考文献17

  • 1Thomas J. Hope and Dider Trono: Structure, Expression and Regulation of the HIV Genome. HIV Insite Knowledge Base.http://www.hivinsite.com
  • 2Misse D, Gajardo J, Oblet C, et al. Soluble HIV-1 gp120 enhances HIV-1 replication in non-dividing CD4 + T cells,mediated via cell signaling and Tat cofactor over expression [J].AIDS,2005,19(9): 897~905
  • 3Bettaccini A A, Baj A, Accolla R S, et al. Proliferative activity of extracellular HIV-1 Tatprotein in human epithelial cells:expression profile of pathogenetically relevant genes [J]. BMC Microbiol. ,2005, 5(1): 20
  • 4Liu B,Yu X,Luo K, et al: Influence of Primate lentiviral vif and proteasome inhibitors on human immunodeficiency virus packaging of APOBEC3G[J]. J. Virology,2004, 78 (4): 2 072~2 081
  • 5Mehle A, Strack B, Ancute P et al. Vif overcome the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway [J]. J. Biol. Chem., 2004, 279(9): 7 792~7 798
  • 6Kewal Ramani VN, Coffin J M. Weapons of mutational destruction[J]. Science, 2003, 301:923~925
  • 7Warner C, Greene M D, B Matijia Peterlin . Molecular Insight Into HIV Biology. HIV Insite Knowledge Base. http://www.hivinsite.com
  • 8Kwong P D, Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelop glycoprotine in complex with the CD4 receptor and a neutralizing human antibody [J] . Nature, 1998, 393 (6 686):648~659
  • 9Liao Z, Cimakasky LM, Hampton R, et al: Lipid rafts and HIV pathogenesis: Host membrane cholesterol is required for infection by HIV type 1 [J]. AIDS Res. Hum. Restroviruses, 2001, 17(11):1 009~1 019
  • 10Kwon D S, Gregorio G , Bitton N, et al. DC-SIGN mediated internalization of HIV is required for trans-enhancement of T cell infection[J]. Immunity, 2002, 16(1): 135~144

同被引文献27

  • 1李海英,李韩平,李敬云,吴昊.经国产齐多夫定、去羟肌苷、奈韦拉平联合抗病毒治疗3个月的艾滋病患者人类免疫缺陷病毒毒株的耐药突变[J].中华传染病杂志,2007,25(2):112-116. 被引量:4
  • 2Hanna GJ, Balaguera HU, Freedberg KA, et al. Drug-selected resistance mutations and non-B subtypes in antiretroviral-naive a- dults with established human immunodeficiency virus infection [J].J Infect Dis, 2003, 188(7): 986--991.
  • 3Cases-Gonzalez CE, S Franco, MA Martinez, et al. Mutational atterns associated with the 69 insertion complex in multi-drug-re- sistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine[J]. J Mol Biol, 2006, 365(2): 298--309.
  • 4Sirivichayakul S, Ruxrungtham K, Ungsedhapand C, et al. Nu- cleoside analogue mutations and Q151M in HIV-1 subtype A/E in~ection treated with nucleoside reverse transcriptase inhibitors[J]. AIDS, 2003, 17(13):1889--1896.
  • 5Petropoulos CJ, Parkin NT, Limoli KL, et al. A noveI pheno- typic drug susceptibility assay for human immunodeficiency virus type [J].Antimicroh Agents Chemother, 2000, 44:920--928.
  • 6Bacheler L, Jeffrey S, Hanna G, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy[J]. J Virol, 2001, 75: 4999--5008.
  • 7Zhang H, Zhao B, Han X, et al. Associations of HLA class I antigen speeificities and haplotypes with disease progres- sion in HIV-l-infected Hans in Northern China [J]. Hum Immunol, 2013, 74 (12): 1636-1642.
  • 8Luque MC, Santos CC, Mairena EC, et al. Gene expression profile in Iong-term nonprogressor HIV infected patients: in search of potential resistance factors [J]. Mol Immunol, 2014, 62 (1): 63-70.
  • 9Kumar P. Long term non-progressor (LTNP) HIV infection [J]. Indian J MedRes, 2013, 138 (3): 291 293.
  • 10Munir S, Thierry S, Subra F, et al. Quantitative analysis of the time-course of viral DNA forms during the HIV-1 life cycle [J]. Retrovirology, 2013, 10: 87.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部